25/06/2020 (Agence Europe) – The European Medicines Agency (EMA) recommended on Thursday 25 June that a conditional marketing authorisation be granted to Veklury (i.e. remdesivir) for the treatment of Covid-19 in adults and adolescents from 12 years of age with severe pneumonia. Remdesivir is the first drug recommended for authorisation in the EU to combat the virus, the agency explains. The study, based on a sample of more than 1,000 patients, would have shown, according to the Agency, that patients treated with remdesivir recovered after about 11 days, compared to 15 days for patients receiving placebo. For patients with severe disease (approximately 90% of the sample), the recovery time was 12 days in the remdesivir-treated group and 18 days in the placebo group. (PH)